Medigene Receives Further European Patent on EndoTAG®-1
May 29 2013 - 1:30AM
Medigene AG / Medigene Receives Further European Patent on
EndoTAG®-1 . Processed and transmitted by Thomson Reuters ONE. The
issuer is solely responsible for the content of this
announcement.
Martinsried/Munich, 29 May 2013. Medigene AG
(Frankfurt, Prime Standard; MDG) announced today that the European
Patent Office has granted a further patent which protects the drug
candidate EndoTAG®-1. The term
of the patent EP 2108362 entitled "A cationic liposomal preparation
comprising a taxane" ends on June 26, 2023.
Dr. Frank
Mathias, Chief Executive Officer of Medigene AG: "The new
patent strengthens the patent position for EndoTAG®-1 in Europe.
We will continue to extend our patent portfolio to ensure
protection of the EndoTAG®-1 product for
Medigene and our partner SynCore."
About
EndoTAG®-1: The clinical drug
candidate EndoTAG®-1 is a novel
composition of the established cytostatic drug paclitaxel combined
with neutral and positive lipids. Because of the positively charged
lipids, EndoTAG®-1 interacts
with newly developed, negatively charged endothelial cells, which
are particularly required for the generation of tumor blood
vessels. The EndoTAG®-1 paclitaxel
component attacks the endothelial cells as they divide, thus
targeting the blood supply to tumors without affecting the blood
supply to healthy tissue. By doing this, EndoTAG®-1 is
expected to prevent the formation of new tumor blood vessels and to
inhibit tumor growth. Medigene has successfully completed two
clinical phase II trials of EndoTAG®-1 in
pancreatic cancer and triple-negative breast cancer (TNBC). The
drug candidate has also shown positive results in a recently
concluded investigator-initiated trial (IIT) in HER2-negative
breast cancer.
Medigene AG
(Frankfurt: MDG, prime standard) is a publicly listed biotechnology
company headquartered in Martinsried/Munich, Germany. Medigene
focuses on clinical research and development of novel drugs against
cancer and autoimmune diseases. Medigene is the first German
biotech company to have revenues from a marketed product
(Veregen®), which is
distributed by partner companies. Medigene has two drug candidates
in clinical trials, EndoTAG®-1 and
RhuDex®, and is
developing an innovative vaccine technology. For more information,
please visit www.medigene.com.
This press release contains
forward-looking statements representing the opinion of Medigene as
of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking
statements made herein. Medigene is not bound to update any of
these forward-looking statements. Medigene® and EndoTAG® are registered trademarks of
Medigene AG. These trademarks may be owned or licensed in select
locations only.
Contact
Julia Hofmann, Claudia
Burmester
Investor & Public Relations
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com
To unsubscribe from the press
release distribution list, please go to
www.medigene.com/unsubscribe.
Press release as PDF
This
announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the
information contained therein.
Source: Medigene AG via Thomson Reuters ONE
HUG#1705294
Meridian Gold (NYSE:MDG)
Historical Stock Chart
From Dec 2024 to Jan 2025
Meridian Gold (NYSE:MDG)
Historical Stock Chart
From Jan 2024 to Jan 2025
